Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$144.35−0.25 (-0.17%)
Close on Nov 17, 2026Market cap $2.08BP/E –Yield –
Palvella Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Palvella Therapeutics's total assets was $253.51M at Jun 30, 2026. For fiscal 2025 it was $59.56M, down 32.5% from the year before. Over ten years it grew 5.8% a year on average. The highest annual figure on record is $153.56M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.56M | -32.5% |
| FY2024 | Dec 31, 2024 | $88.23M | +1069.0% |
| FY2023 | Dec 31, 2023 | $7.55M | -92.1% |
| FY2022 | Dec 31, 2022 | $95.49M | -37.8% |
| FY2021 | Dec 31, 2021 | $153.56M | +46.2% |
| FY2020 | Dec 31, 2020 | $105.01M | -25.6% |
| FY2019 | Dec 31, 2019 | $141.10M | -0.2% |
| FY2018 | Dec 31, 2018 | $141.34M | +36.1% |
| FY2017 | Dec 31, 2017 | $103.88M | +196.3% |
| FY2016 | Dec 31, 2016 | $35.06M | +3.3% |
| FY2015 | Dec 31, 2015 | $33.95M | +55.3% |
| FY2014 | Dec 31, 2014 | $21.86M | +200.4% |
| FY2013 | Dec 31, 2013 | $7.28M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $253.51M | +243.8% |
| Q1 FY2026 | Mar 31, 2026 | $263.76M | +232.0% |
| Q4 FY2025 | Dec 31, 2025 | $59.56M | -32.5% |
| Q3 FY2025 | Sep 30, 2025 | $66.94M | +226.2% |
| Q2 FY2025 | Jun 30, 2025 | $73.75M | +194.4% |
| Q1 FY2025 | Mar 31, 2025 | $79.44M | +169.3% |
| Q4 FY2024 | Dec 31, 2024 | $88.23M | +1069.0% |
| Q3 FY2024 | Sep 30, 2024 | $20.52M | -65.4% |
| Q2 FY2024 | Jun 30, 2024 | $25.05M | -71.4% |
| Q1 FY2024 | Mar 31, 2024 | $29.50M | -64.1% |
| Q4 FY2023 | Dec 31, 2023 | $7.55M | -92.1% |
| Q3 FY2023 | Sep 30, 2023 | $59.38M | -40.1% |
| Q2 FY2023 | Jun 30, 2023 | $87.54M | -23.4% |
| Q1 FY2023 | Mar 31, 2023 | $82.26M | -40.0% |
| Q4 FY2022 | Dec 31, 2022 | $95.49M | -37.8% |
| Q3 FY2022 | Sep 30, 2022 | $99.16M | -39.6% |
| Q2 FY2022 | Jun 30, 2022 | $114.31M | -26.3% |
| Q1 FY2022 | Mar 31, 2022 | $137.12M | +18.4% |
| Q4 FY2021 | Dec 31, 2021 | $153.56M | +46.2% |
| Q3 FY2021 | Sep 30, 2021 | $164.18M | +41.9% |
| Q2 FY2021 | Jun 30, 2021 | $155.03M | +31.6% |
| Q1 FY2021 | Mar 31, 2021 | $115.79M | -6.5% |
| Q4 FY2020 | Dec 31, 2020 | $105.01M | -25.6% |
| Q3 FY2020 | Sep 30, 2020 | $115.72M | -0.9% |
| Q2 FY2020 | Jun 30, 2020 | $117.78M | -10.0% |
| Q1 FY2020 | Mar 31, 2020 | $123.77M | -5.6% |
| Q4 FY2019 | Dec 31, 2019 | $141.10M | -0.2% |
| Q3 FY2019 | Sep 30, 2019 | $116.75M | -23.0% |
| Q2 FY2019 | Jun 30, 2019 | $130.84M | -19.2% |
| Q1 FY2019 | Mar 31, 2019 | $131.05M | -24.4% |
| Q4 FY2018 | Dec 31, 2018 | $141.34M | +36.1% |
| Q3 FY2018 | Sep 30, 2018 | $151.66M | +53.4% |
| Q2 FY2018 | Jun 30, 2018 | $162.03M | +52.9% |
| Q1 FY2018 | Mar 31, 2018 | $173.24M | +180.0% |
| Q4 FY2017 | Dec 31, 2017 | $103.88M | +196.3% |
| Q3 FY2017 | Sep 30, 2017 | $98.86M | +126.2% |
| Q2 FY2017 | Jun 30, 2017 | $105.96M | – |
| Q1 FY2017 | Mar 31, 2017 | $61.88M | – |
| Q4 FY2016 | Dec 31, 2016 | $35.06M | – |
| Q3 FY2016 | Sep 30, 2016 | $43.71M | – |
See a number that looks wrong?